Evolent Health Financial Statements (EVH)
|
|
|
|
Report date
|
|
|
24.02.2022 |
24.02.2023 |
23.02.2024 |
21.02.2025 |
25.02.2026 |
|
25.02.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
908.0 |
1 352 |
1 964 |
2 555 |
1 876 |
|
1 876 |
|
Operating Income, bln rub |
|
|
-42.4 |
3.64 |
-71.2 |
-40.5 |
-4.43 |
|
-11.5 |
|
EBITDA, bln rub |
? |
|
55.7 |
43.7 |
-24.8 |
84.9 |
-361.3 |
|
-361.3 |
|
Net profit, bln rub |
? |
|
-37.6 |
-19.2 |
-113.0 |
-61.6 |
-534.5 |
|
-534.5 |
|
|
OCF, bln rub |
? |
|
38.7 |
-11.6 |
142.6 |
18.8 |
38.8 |
|
38.8 |
|
CAPEX, bln rub |
? |
|
25.0 |
38.4 |
28.7 |
24.9 |
34.1 |
|
34.1 |
|
FCF, bln rub |
? |
|
13.8 |
-49.9 |
113.8 |
-6.13 |
4.76 |
|
4.76 |
|
Dividend payout, bln rub
|
|
|
1.30 |
0.000 |
0.000 |
20.1 |
0.000 |
|
9.20 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
-1.72% |
|
|
OPEX, bln rub |
|
|
292.8 |
312.9 |
531.7 |
407.8 |
287.5 |
|
321.6 |
|
Cost of production, bln rub |
|
|
657.6 |
1 035 |
1 503 |
2 187 |
1 593 |
|
1 593 |
|
R&D, bln rub |
|
|
0.000 |
27.0 |
0.000 |
0.000 |
0.000 |
|
0.006 |
|
Interest expenses, bln rub |
|
|
25.4 |
15.6 |
54.2 |
24.7 |
57.5 |
|
57.5 |
|
|
Assets, bln rub |
|
|
1 419 |
1 817 |
2 680 |
2 544 |
1 899 |
|
1 899 |
|
Net Assets, bln rub |
? |
|
693.6 |
859.4 |
1 068 |
1 001 |
415.2 |
|
415.2 |
|
Debt, bln rub |
|
|
280.5 |
476.1 |
644.8 |
713.7 |
989.7 |
|
989.7 |
|
Cash, bln rub |
|
|
266.3 |
188.2 |
192.8 |
163.5 |
151.9 |
|
151.9 |
|
Net debt, bln rub |
|
|
14.2 |
287.9 |
452.0 |
550.2 |
837.8 |
|
837.8 |
|
|
Ordinary share price, rub |
|
|
27.7 |
28.1 |
33.0 |
11.3 |
4.00 |
|
3.84 |
|
Number of ordinary shares, mln |
|
|
86.1 |
93.7 |
111.3 |
114.7 |
114.2 |
|
114.2 |
|
|
Market cap, bln rub |
|
|
2 381 |
2 631 |
3 675 |
1 290 |
457 |
|
438 |
|
EV, bln rub |
? |
|
2 396 |
2 919 |
4 127 |
1 840 |
1 295 |
|
1 276 |
|
Book value, bln rub |
|
|
-12 |
-306 |
-801 |
-816 |
-864 |
|
-864 |
|
|
EPS, rub |
? |
|
-0.44 |
-0.20 |
-1.02 |
-0.54 |
-4.68 |
|
-4.68 |
|
FCF/share, rub |
|
|
0.16 |
-0.53 |
1.02 |
-0.05 |
0.04 |
|
0.04 |
|
BV/share, rub |
|
|
-0.14 |
-3.27 |
-7.20 |
-7.12 |
-7.57 |
|
-7.57 |
|
|
EBITDA margin, % |
? |
|
6.13% |
3.24% |
-1.26% |
3.32% |
-19.3% |
|
-19.3% |
|
Net margin, % |
? |
|
-4.14% |
-1.42% |
-5.76% |
-2.41% |
-28.5% |
|
-28.5% |
|
FCF yield, % |
? |
|
0.58% |
-1.90% |
3.10% |
-0.47% |
1.04% |
|
1.09% |
|
ROE, % |
? |
|
-5.42% |
-2.23% |
-10.6% |
-6.15% |
-128.7% |
|
-128.7% |
|
ROA, % |
? |
|
-2.65% |
-1.05% |
-4.22% |
-2.42% |
-28.1% |
|
-28.1% |
|
|
P/E |
? |
|
-63.3 |
-137.3 |
-32.5 |
-20.9 |
-0.85 |
|
-0.82 |
|
P/FCF |
|
|
173.0 |
-52.7 |
32.3 |
-210.5 |
96.1 |
|
92.1 |
|
P/S |
? |
|
2.62 |
1.95 |
1.87 |
0.51 |
0.24 |
|
0.23 |
|
P/BV |
? |
|
-191.3 |
-8.59 |
-4.59 |
-1.58 |
-0.53 |
|
-0.51 |
|
EV/EBITDA |
? |
|
43.0 |
66.7 |
-166.5 |
21.7 |
-3.58 |
|
-3.53 |
|
Debt/EBITDA |
|
|
0.25 |
6.58 |
-18.2 |
6.48 |
-2.32 |
|
-2.32 |
|
|
R&D/CAPEX, % |
|
|
0.00% |
70.4% |
0.00% |
0.00% |
0.00% |
|
0.02% |
|
|
CAPEX/Revenue, % |
|
|
2.75% |
2.84% |
1.46% |
0.97% |
1.82% |
|
1.82% |
|
| Evolent Health shareholders |
